Psilocybin-Research.com
Research. Clarity. Progress.
Executed search
Sources: Europe PMC
2,554 matching records are displayed.
Clear search Latest Publications
Most recently published records currently stored in SQLite.
1-20
Last updated: Jul 3, 2026 01:22 UTC
Checking for newly published papers…
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
ClinicalTrials.gov · 2026-07-01
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
DMT und Ayahuasca / DMT and Ayahuasca
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia
Revista CienciaUANL · 2026-06-30
Meskalin / Mescaline
Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30
Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión
Multidisciplinary Collaborative Journal · 2026-06-30
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
Journal of Drug Issues · 2026-06-30
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
ClinicalTrials.gov · 2026-06-30
Psilocybin shows mixed results for patients with treatment-resistant depression
The Brown University Psychopharmacology Update · 2026-06-30
Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation
The Brown University Psychopharmacology Update · 2026-06-30
Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review
Journal of Affective Disorders Reports · 2026-06-30
Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.
Palliative medicine · 2026-06-30
Record check: Jul 3, 2026 01:22 UTC
Daily cron-ready
2,554matching papers
3,834psilocybin
553psilocin
388journals
3,975all time
Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.
Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, inclu...
Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review.
Disorders of consciousness pose major therapeutic challenges owing to the complexity of underlying brain dysfunctions. Current pharmacological interventions explored in disorders of consciousness target distinct molecular systems, including dopaminergic modulators (amantadine, levodopa, apomorphine, bromocriptine, selegiline, methylphenidate, and modafinil),...
The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.
IntroductionThe contribution of patient support to psilocybin's antidepressant effects remains uncertain.MethodsRelationships between therapeutic alliance (Scale to Assess Therapeutic Relationship-Patient version; STAR-P), psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire and Emotional Breakthrough Inventory; 5D-ASC and E...
Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis.
ObjectiveThis systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD).MethodsSeparate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 ...
Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.
Psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are psychedelic compounds with therapeutic potential for depression, anxiety, and post-traumatic stress. However, their relevance to endurance athletes, who face particular psychological and physical stressors, remains underexplored. This ...
Beyond the Genomic Storm: Evaluating Tabernanthalog as a Potential Scaffold for Silent Neuroplasticity and Broad-Spectrum Therapy.
The clinical renaissance of psychedelic medicine has highlighted the therapeutic potential of rapid-acting neuroplastogens, or "psychoplastogens," for psychiatric disorders. However, the widespread application of classical psychedelics-such as psilocybin and LSD-and the atypical dissociative ibogaine is severely limited by their hallucinogenic properties and...
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review.
RationaleThe nature and role of the psychological support provided in psychedelic-assisted treatments for psychiatric disorders are currently the object of debate. How this support is conceptualized-as a vector for therapeutic change or framework for risk minimization-has far-reaching consequences in terms of how these treatments should be regulated, deliver...
Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies.
Psilocybin-assisted therapies are innovative therapeutic approaches, particularly in the treatment of depression. However, there are sparse studies providing functional magnetic resonance imaging (fMRI) evidence elucidating the underlying biological mechanisms that support clinical outcomes. This review aims to comprehensively gather all the evidence reporte...
Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distribution.
IntroductionThe use of psychedelics has increased in Canada in recent years. Although non-medical psilocybin use is prohibited under the Controlled Drugs and Substances Act, we previously documented the emergence of grey-market brick-and-mortar psilocybin retailers. This study examined changes in the number, composition, and geographic distribution of Canadi...
Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression.
BackgroundTreatment-resistant depression (TRD) imposes a substantial public health and economic burden. Although psilocybin-assisted therapy (PAT) has shown clinical promise, its economic value remains uncertain. This study evaluated the cost-effectiveness of PAT compared with the standard of care for TRD.MethodsA Markov model adopting a US healthcare perspe...
Psychedelic Terminology Preference in the 2024 National Survey Investigating Hallucinogenic Trends (NSIHT).
Expanding regulation and increased use of psychedelic substances requires surveillance of behaviors and health outcomes in the United States. Widely comprehendible terminology is important for surveys. The objective of this study was to determine what psychedelic terminology is preferred among adults who used a psychedelic in the past 12 months. A cross-sect...
The renaissance of research on psychedelics in child and adolescent psychopharmacology.
AIMS: The recent regulatory approval of esketamine in adults heralded the renaissance of research into psychedelic compounds. However, the relevance of this resurgence for children and adolescents remains unclear. This review examines the rationale for investigating psychedelics in pediatric psychopharmacology. METHODS: We reviewed recent literature, regulat...
A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder.
BackgroundCurrent treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed.AimsThis randomized clinical trial evaluated safety, tolerability, and benefi...
Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review.
Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schi...
Digital Intervention for Psychedelic Preparation (DIPP): protocol for a randomised controlled feasibility trial comparing meditation- and music-based programmes in healthy volunteers.
IntroductionPsychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application. Digital health interventions have the potential to address this limitation by providing structured, accessible and scalable preparation solutions. This randomised co...
Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they ac...
Age moderates the relationship between psychedelics use and mental health in naturalistic settings
Abstract Depression and anxiety affect one in five adults, with age affecting prevalence. While clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these relationships function in naturalistic settings or how they vary across the lifespan...
Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report
Abstract Background: This case describes a substance-induced manic episode with psychotic features in which interaction with an AI (artificial intelligence) chatbot appeared to corroborate and reinforce the patient’s delusional thought content and to contradict medical advice. Excerpts from the patient’s interactions with the AI chatbot provide novel clinica...
Psilocybin microdosing in the United States: Insights from a nationally representative survey.
Background and aimsThere has been a resurgence of interest in using psilocybin to treat various mental health conditions. Although some adults in the United States (US) are using psilocybin, little is known about the epidemiology of its use, especially for microdosing (i.e., taking a fraction of a regular dose). This study aimed to present nationally represe...
5 Years of bipolar disorder conversations on Reddit: Methods, key topics and future directions.
Bipolar disorder (BD) is a prevalent mood disorder that can be associated with serious personal, societal, and economic costs. Growing attention is being paid to the importance of including the experiences of people living with BD in research and healthcare system advancement. However, there is still much to be learned about what people with BD are prioritiz...